- Home
- CIFR vs AGIO Comparison
CIFR vs AGIO Comparison
Compare CIFR & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIFR
- AGIO
- Stock Information
- Founded
- CIFR 2021
- AGIO 2007
- Country
- CIFR United States
- AGIO United States
- Employees
- CIFR N/A
- AGIO N/A
- Industry
- CIFR Investment Bankers/Brokers/Service
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- CIFR Finance
- AGIO Health Care
- Exchange
- CIFR Nasdaq
- AGIO Nasdaq
- Market Cap
- CIFR 1.9B
- AGIO 2.0B
- IPO Year
- CIFR N/A
- AGIO 2013
- Fundamental
- Price
- CIFR $5.49
- AGIO $35.22
- Analyst Decision
- CIFR Strong Buy
- AGIO Buy
- Analyst Count
- CIFR 10
- AGIO 7
- Target Price
- CIFR $7.83
- AGIO $56.33
- AVG Volume (30 Days)
- CIFR 13.7M
- AGIO 621.1K
- Earning Date
- CIFR 02-25-2025
- AGIO 02-13-2025
- Dividend Yield
- CIFR N/A
- AGIO N/A
- EPS Growth
- CIFR N/A
- AGIO N/A
- EPS
- CIFR N/A
- AGIO 11.64
- Revenue
- CIFR $152,466,000.00
- AGIO $36,498,000.00
- Revenue This Year
- CIFR $20.12
- AGIO $166.22
- Revenue Next Year
- CIFR $123.56
- AGIO $98.36
- P/E Ratio
- CIFR N/A
- AGIO $3.03
- Revenue Growth
- CIFR 76.34
- AGIO 36.07
- 52 Week Low
- CIFR $2.66
- AGIO $27.14
- 52 Week High
- CIFR $7.99
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- CIFR 46.95
- AGIO 54.02
- Support Level
- CIFR $5.85
- AGIO $33.25
- Resistance Level
- CIFR $6.33
- AGIO $34.86
- Average True Range (ATR)
- CIFR 0.48
- AGIO 1.33
- MACD
- CIFR 0.01
- AGIO 0.37
- Stochastic Oscillator
- CIFR 27.82
- AGIO 97.99
About CIFR Cipher Mining Inc.
Cipher Mining Inc ia an emerging technology company that operates in the Bitcoin mining ecosystem in the United States. The company is developing a cryptocurrency mining business, specializing in Bitcoin. The company is expanding and strengthening the Bitcoin network's critical infrastructure in the United States.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.